share_log

SIGA Technologies (NASDAQ:SIGA) Reaches New 52-Week High at $23.00

SIGA Technologies (NASDAQ:SIGA) Reaches New 52-Week High at $23.00

SIGA科技(納斯達克:SIGA)漲至23.00美元,創52周新高
Defense World ·  2022/08/07 15:21

SIGA Technologies, Inc. (NASDAQ:SIGA – Get Rating)'s share price reached a new 52-week high on Friday . The stock traded as high as $23.00 and last traded at $22.26, with a volume of 250343 shares traded. The stock had previously closed at $19.47.

上週五,SIGA科技公司(納斯達克代碼:SIGA-GET Rating)的股價創下52周新高。該股最高交易價格為2300美元,最新報22.26美元,成交量為250343股。該股此前收盤報19.47美元。

Analyst Ratings Changes

分析師評級發生變化

Separately, TheStreet downgraded SIGA Technologies from a "b" rating to a "c+" rating in a research note on Monday, May 23rd.

另外,華爾街在5月23日星期一的一份研究報告中將SIGA Technologies的評級從“b”下調至“c+”。

Get
到達
SIGA Technologies
SIGA技術
alerts:
警報:

SIGA Technologies Stock Performance

SIGA科技股表現

The firm has a market capitalization of $1.69 billion, a P/E ratio of 24.27 and a beta of 0.63. The firm has a 50-day moving average of $13.56 and a 200-day moving average of $9.35.

該公司的市值為16.9億美元,市盈率為24.27,貝塔係數為0.63。該公司的50日移動均線切入位在13.56美元,200日移動均線切入位在9.35美元。

SIGA Technologies (NASDAQ:SIGA – Get Rating) last released its quarterly earnings data on Thursday, May 5th. The company reported ($0.01) earnings per share (EPS) for the quarter. The business had revenue of $10.54 million during the quarter. SIGA Technologies had a net margin of 48.67% and a return on equity of 47.99%. On average, research analysts forecast that SIGA Technologies, Inc. will post 0.66 EPS for the current fiscal year.
SIGA科技(納斯達克:SIGA-GET Rating)最近一次發佈季度收益數據是在5月5日星期四。該公司公佈了該季度每股收益(EPS)(0.01美元)。該業務本季度營收為1,054萬美元。SIGA Technologies的淨利潤率為48.67%,股本回報率為47.99%。研究分析師平均預測,SIGA Technologies,Inc.本財年每股收益將為0.66歐元。

Hedge Funds Weigh In On SIGA Technologies

對衝基金買入SIGA Technologies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Advisor Group Holdings Inc. lifted its position in SIGA Technologies by 625.0% in the 4th quarter. Advisor Group Holdings Inc. now owns 17,400 shares of the company's stock valued at $131,000 after acquiring an additional 15,000 shares in the last quarter. Exchange Traded Concepts LLC bought a new position in shares of SIGA Technologies during the 1st quarter valued at $512,000. BNP Paribas Arbitrage SA lifted its holdings in shares of SIGA Technologies by 257.9% during the 4th quarter. BNP Paribas Arbitrage SA now owns 32,038 shares of the company's stock valued at $241,000 after buying an additional 23,087 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of SIGA Technologies by 44.9% during the 4th quarter. Renaissance Technologies LLC now owns 893,504 shares of the company's stock valued at $6,719,000 after buying an additional 276,814 shares during the period. Finally, Principal Financial Group Inc. lifted its holdings in shares of SIGA Technologies by 254.0% during the 4th quarter. Principal Financial Group Inc. now owns 37,837 shares of the company's stock valued at $285,000 after buying an additional 27,149 shares during the period. 34.52% of the stock is owned by institutional investors.

對衝基金和其他機構投資者最近增持或減持了該業務的股份。Advisor Group Holdings Inc.在第四季度將其在SIGA Technologies的持倉提高了625.0%。Advisor Group Holdings Inc.在上個季度增持了15,000股後,現在持有17,400股該公司股票,價值13.1萬美元。交易所交易的Concepts LLC在第一季度購買了SIGA Technologies的新頭寸,價值51.2萬美元。法國巴黎銀行套利公司在第四季度增持了SIGA Technologies的股票257.9%。法國巴黎銀行套利公司現在持有32,038股該公司股票,價值241,000美元,在此期間又購買了23,087股。復興科技有限責任公司在第四季度增持了SIGA科技公司的股票44.9%。復興科技有限責任公司現在擁有該公司893,504股股票,價值6,719,000美元,在此期間又購買了276,814股。最後,信安金融集團在第四季度增持了SIGA Technologies的股票254.0%。信安金融集團目前持有該公司37,837股股票,價值28.5萬美元,在此期間又購買了27,149股。34.52%的股份由機構投資者持有。

About SIGA Technologies

關於SIGA技術

(Get Rating)

(獲取評級)

SIGA Technologies, Inc, a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats.

SIGA Technologies,Inc.是一家商業階段的製藥公司,專注於美國的健康安全和傳染病市場。其主導產品是TPOXX,一種口服制劑抗病毒藥物,用於治療由天花病毒引起的人類天花疾病。SIGA Technologies,Inc.與Cipla治療公司建立了戰略合作伙伴關係,以提供持續的創新和獲得主要針對生物療法的抗菌藥物。

Further Reading

進一步閲讀

  • Get a free copy of the StockNews.com research report on SIGA Technologies (SIGA)
  • MarketBeat: Week in Review 8/1 – 8/5
  • How to Use High Beta Stocks to Maximize Your Investing Profits
  • Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
  • Beyond Meat Is Not Beyond Hope, And It's Cheap
  • Why Apple Could Be At All-Time Highs By Year End
  • 免費獲取StockNews.com關於SIGA技術的研究報告(SIGA)
  • MarketBeat:回顧中的一週8/1-8/5
  • 如何利用高貝塔係數股票最大化你的投資利潤
  • 克羅諾斯集團(Cronos Group Inc.)營收上升,是時候收購了嗎?
  • Beyond Meat不是沒有希望,而且它很便宜
  • 蘋果為何可能在年底創下歷史新高

Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

接受SIGA技術日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對SIGA Technologies和相關公司的最新新聞和分析師評級的每日簡要摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論